ELOXX PHARMACEUTICALS, INC. Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments
ELOXX PHARMACEUTICALS, INC. (ELOX) reported Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments of $0 for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.
Discontinued › Income Statement › Other Income
us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1 · last filed 2017-11-14
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2017-09-30 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2017-06-30 was -$223.17K.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2017-03-31 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for the quarter ending 2016-12-31 was $223.17K.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2016 was $254.03K, a 1947.78% increase from fiscal 2015.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2015 was $12.40K.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2014 was $0.00.
- ELOXX PHARMACEUTICALS, INC. change in unrealized gain (loss) on fair value hedging instruments for fiscal 2013 was $0.00.
| Period end | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 3 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 6 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 9 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 12 month | Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 12 month as first filed |
|---|---|---|---|---|---|
| 2017-09-30 | $0.00 10-Q · filed 2017-11-14 | -$223.17K derived: sum of 2 quarters · filed 2017-11-14 | -$223.17K derived: sum of 3 quarters · filed 2017-11-14 | $0.00 derived: sum of 4 quarters · filed 2017-11-14 | |
| 2017-06-30 | -$223.17K derived: 10-Q 12 month − 10-Q 9 month · filed 2017-11-14 | -$223.17K derived: sum of 2 quarters · filed 2017-11-14 | $0.00 derived: sum of 3 quarters · filed 2017-11-14 | $428.31K 10-Q · filed 2017-11-14 | $651.48K 10-K · filed 2017-10-13 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-22 | $223.17K derived: sum of 2 quarters · filed 2017-05-22 | $651.48K 10-Q · filed 2017-05-22 | $589.65K derived: sum of 4 quarters · filed 2017-10-13 | |
| 2016-12-31 | $223.17K 10-Q · filed 2017-02-10 | $651.48K 10-Q · filed 2017-02-10 | $589.65K derived: sum of 3 quarters · filed 2017-10-13 | $1.33M derived: sum of 4 quarters · filed 2017-10-13 | |
| 2016-09-30 | $428.31K 10-Q · filed 2016-11-14 | $366.48K derived: sum of 2 quarters · filed 2017-10-13 | $1.11M derived: sum of 3 quarters · filed 2017-10-13 | $660.01K derived: sum of 4 quarters · filed 2017-10-13 | |
| 2016-06-30 | -$61.84K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $680.42K derived: sum of 2 quarters · filed 2017-10-13 | $231.69K derived: sum of 3 quarters · filed 2017-10-13 | $254.03K 10-K · filed 2017-10-13 | |
| 2016-03-31 | $742.25K 10-Q · filed 2017-05-22 | $293.53K derived: sum of 2 quarters · filed 2017-05-22 | $315.86K 10-Q · filed 2017-05-22 | $328.27K derived: sum of 4 quarters · filed 2017-10-13 | |
| 2015-12-31 | -$448.73K 10-Q · filed 2017-02-10 | -$426.39K 10-Q · filed 2017-02-10 | -$413.99K derived: sum of 3 quarters · filed 2017-10-13 | -$413.99K derived: sum of 4 quarters · filed 2017-10-13 | |
| 2015-09-30 | $22.33K 10-Q · filed 2016-11-14 | $34.74K derived: sum of 2 quarters · filed 2017-10-13 | $34.74K derived: sum of 3 quarters · filed 2017-10-13 | $34.74K derived: sum of 4 quarters · filed 2017-10-13 | |
| 2015-06-30 | $12.40K derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $12.40K derived: sum of 2 quarters · filed 2017-10-13 | $12.40K derived: sum of 3 quarters · filed 2017-10-13 | $12.40K 10-K · filed 2017-10-13 | |
| 2015-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-12 | $0.00 derived: sum of 2 quarters · filed 2016-05-12 | $0.00 10-Q · filed 2016-05-12 | ||
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-16 | $0.00 10-Q · filed 2016-02-16 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-11-16 | ||||
| 2014-06-30 | $0.00 10-K · filed 2016-10-13 | ||||
| 2013-06-30 | $0.00 10-K · filed 2015-10-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |